557 lines
No EOL
108 KiB
HTML
557 lines
No EOL
108 KiB
HTML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK65741" /><meta name="ncbi_domain" content="pdqcis" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK65741.4/" /><meta name="ncbi_pagename" content="Hairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Hairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="PDQ Cancer Information Summaries [Internet]" /><meta name="citation_title" content="Hairy Cell Leukemia Treatment (PDQ®)" /><meta name="citation_publisher" content="National Cancer Institute (US)" /><meta name="citation_date" content="2020/11/25" /><meta name="citation_author" content="PDQ Adult Treatment Editorial Board" /><meta name="citation_pmid" content="26389184" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK65741/" /><meta name="citation_keywords" content="hairy cell leukemia" /><meta name="citation_keywords" content="hairy cell leukemia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Hairy Cell Leukemia Treatment (PDQ®)" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Cancer Institute (US)" /><meta name="DC.Contributor" content="PDQ Adult Treatment Editorial Board" /><meta name="DC.Date" content="2020/11/25" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK65741/" /><meta name="description" content="Hairy cell leukemia treatment options include surveillance, chemotherapy, targeted therapy/immunotherapy, and splenectomy. The decision to treat is based on cytopenias, splenomegaly, or infectious complications. Get detailed information about hairy cell leukemia in this clinician summary." /><meta name="og:title" content="Hairy Cell Leukemia Treatment (PDQ®)" /><meta name="og:type" content="book" /><meta name="og:description" content="Hairy cell leukemia treatment options include surveillance, chemotherapy, targeted therapy/immunotherapy, and splenectomy. The decision to treat is based on cytopenias, splenomegaly, or infectious complications. Get detailed information about hairy cell leukemia in this clinician summary." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK65741/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/pdqcis/CDR0000062926/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK65741/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script><meta name="book-collection" content="NONE" />
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CFF207C9578F100000000010000D1.m_13" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/4207974/4206132/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-part">
|
|
<div class="grid">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
<div id="universal_header">
|
|
<section class="usa-banner">
|
|
<div class="usa-accordion">
|
|
<header class="usa-banner-header">
|
|
<div class="usa-grid usa-banner-inner">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
|
|
<p>An official website of the United States government</p>
|
|
<button class="non-usa-accordion-button usa-banner-button" aria-expanded="false" aria-controls="gov-banner-top" type="button">
|
|
<span class="usa-banner-button-text">Here's how you know</span>
|
|
</button>
|
|
</div>
|
|
</header>
|
|
<div class="usa-banner-content usa-grid usa-accordion-content" id="gov-banner-top" aria-hidden="true">
|
|
<div class="usa-banner-guidance-gov usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg" alt="Dot gov" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The .gov means it's official.</strong>
|
|
<br />
|
|
Federal government websites often end in .gov or .mil. Before
|
|
sharing sensitive information, make sure you're on a federal
|
|
government site.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
<div class="usa-banner-guidance-ssl usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg" alt="Https" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The site is secure.</strong>
|
|
<br />
|
|
The <strong>https://</strong> ensures that you are connecting to the
|
|
official website and that any information you provide is encrypted
|
|
and transmitted securely.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<div class="usa-overlay"></div>
|
|
<header class="ncbi-header" role="banner" data-section="Header">
|
|
|
|
<div class="usa-grid">
|
|
<div class="usa-width-one-whole">
|
|
|
|
<div class="ncbi-header__logo">
|
|
<a href="/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
|
|
</a>
|
|
</div>
|
|
|
|
<div class="ncbi-header__account">
|
|
<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
|
|
<button id="account_info" class="header-button" style="display:none" aria-controls="account_popup" type="button">
|
|
<span class="fa fa-user" aria-hidden="true">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="20px" height="20px">
|
|
<g style="fill: #fff">
|
|
<ellipse cx="12" cy="8" rx="5" ry="6"></ellipse>
|
|
<path d="M21.8,19.1c-0.9-1.8-2.6-3.3-4.8-4.2c-0.6-0.2-1.3-0.2-1.8,0.1c-1,0.6-2,0.9-3.2,0.9s-2.2-0.3-3.2-0.9 C8.3,14.8,7.6,14.7,7,15c-2.2,0.9-3.9,2.4-4.8,4.2C1.5,20.5,2.6,22,4.1,22h15.8C21.4,22,22.5,20.5,21.8,19.1z"></path>
|
|
</g>
|
|
</svg>
|
|
</span>
|
|
<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
|
|
<span class="sr-only">Show account info</span>
|
|
</button>
|
|
</div>
|
|
|
|
<div class="ncbi-popup-anchor">
|
|
<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
|
|
<div class="ncbi-popup-head">
|
|
<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu" type="button">
|
|
<span class="fa fa-times">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" height="24px">
|
|
<path d="M38 12.83l-2.83-2.83-11.17 11.17-11.17-11.17-2.83 2.83 11.17 11.17-11.17 11.17 2.83 2.83 11.17-11.17 11.17 11.17 2.83-2.83-11.17-11.17z"></path>
|
|
</svg>
|
|
</span>
|
|
<span class="usa-sr-only">Close</span></button>
|
|
<h4>Account</h4>
|
|
</div>
|
|
<div class="account-user-info">
|
|
Logged in as:<br />
|
|
<b><span class="username" id="uname_long">username</span></b>
|
|
</div>
|
|
<div class="account-links">
|
|
<ul class="usa-unstyled-list">
|
|
<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
|
|
<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
|
|
<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
|
|
<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
|
|
</ul>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
</div>
|
|
</header>
|
|
<div role="navigation" aria-label="access keys">
|
|
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
|
|
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
|
|
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
|
|
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
|
|
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
|
|
</div>
|
|
<section data-section="Alerts">
|
|
<div class="ncbi-alerts-placeholder"></div>
|
|
</section>
|
|
</div>
|
|
<div class="header">
|
|
<div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
|
|
<div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" data-ac_dict="bookshelf-search">Books</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="clinvar" class="last">ClinVar</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
|
|
<a href="/books/browse/">Browse Titles</a>
|
|
</li><li>
|
|
<a href="/books/advanced/">Advanced</a>
|
|
</li><li class="help">
|
|
<a href="/books/NBK3833/">Help</a>
|
|
</li><li class="disclaimer">
|
|
<a target="_blank" data-ga-category="literature_resources" data-ga-action="link_click" data-ga-label="disclaimer_link" href="https://www.ncbi.nlm.nih.gov/books/about/disclaimer/">Disclaimer</a>
|
|
</li></ul></div>
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<!-- Custom content 1 -->
|
|
<div class="col1">
|
|
|
|
</div>
|
|
|
|
<div class="container">
|
|
<div id="maincontent" class="content eight_col col">
|
|
<!-- Custom content in the left column above book nav -->
|
|
<div class="col2">
|
|
|
|
</div>
|
|
|
|
<!-- Book content -->
|
|
|
|
|
|
<!-- Custom content between navigation and content -->
|
|
<div class="col3">
|
|
|
|
</div>
|
|
|
|
<div class="document">
|
|
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="Table of Contents Page" href="/books/n/pdqcis/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" alt="Cover of PDQ Cancer Information Summaries" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>PDQ Cancer Information Summaries [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK65741_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK65741_dtls__"><div>Bethesda (MD): <a href="http://www.cancer.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>; 2002-.</div></div><div class="half_rhythm"></div><div class="bk_noprnt"><form method="get" action="/books/n/pdqcis/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div></div></div></div>
|
|
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK65741_"><span class="title" itemprop="name">Hairy Cell Leukemia Treatment (PDQ®)</span></h1><div class="subtitle whole_rhythm">Health Professional Version</div><p class="contrib-group"><span itemprop="author">PDQ Adult Treatment Editorial Board</span>.</p><p class="small">Published online: November 25, 2020.</p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p id="CDR0000062926__110">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of hairy cell leukemia. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p><p id="CDR0000062926__111">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p></div><div id="CDR0000062926__1"><h2 id="_CDR0000062926__1_">General Information About Hairy Cell Leukemia</h2><div id="CDR0000062926__105"><h3>Prognostic Factors</h3><p id="CDR0000062926__99">Hairy cell leukemia is an indolent, low-grade, B-cell lymphoma usually characterized by the following:</p><ul id="CDR0000062926__100"><li class="half_rhythm"><div>Circulating B-cells with cytoplasmic projections ("hairy" appearance).</div></li><li class="half_rhythm"><div>Splenomegaly.</div></li><li class="half_rhythm"><div>Absent lymphadenopathy.</div></li><li class="half_rhythm"><div>Pancytopenia.</div></li><li class="half_rhythm"><div>Monocytopenia.</div></li></ul></div><div id="CDR0000062926__106"><h3>Diagnosis</h3><p id="CDR0000062926__104">In addition to the B-cell antigens CD19, CD20, and CD22, the cells coexpress CD11c, CD25, and CD103. The <i>BRAF</i>-V600E mutation is a hairy cell leukemia–defining genetic lesion that can be used diagnostically.[<a class="bk_pop" href="#CDR0000062926_rl_1_1">1</a>,<a class="bk_pop" href="#CDR0000062926_rl_1_2">2</a>] The decision to treat is based on symptomatic cytopenias, massive
|
|
splenomegaly, or the presence of other complications. About 10% of all
|
|
patients will never require therapy.
|
|
</p></div><div id="CDR0000062926_rl_1"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062926_rl_1_1">Tiacci E, Schiavoni G, Forconi F, et al.: Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 119 (1): 192-5, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22028477" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22028477</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_1_2">Naik RR, Saven A: My treatment approach to hairy cell leukemia. Mayo Clin Proc 87 (1): 67-76, 2012. [<a href="/pmc/articles/PMC3498175/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3498175</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22212971" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22212971</span></a>]</div></li></ol></div></div><div id="CDR0000062926__3"><h2 id="_CDR0000062926__3_">Stage Information for Hairy Cell Leukemia</h2><p id="CDR0000062926__4">No generally accepted staging system is useful for both prognosis
|
|
and therapy.
|
|
</p><p id="CDR0000062926__7">Untreated hairy cell leukemia is characterized by splenomegaly, varying degrees
|
|
of leukopenia (occasionally leukocytosis) and/or pancytopenia, and bone marrow
|
|
infiltration by an atypical cell with prominent cytoplasmic projections (i.e., hairy
|
|
cells). The bone marrow is usually fibrotic and is not easily aspirated;
|
|
therefore, bone marrow biopsies are required for diagnosis and evaluation of the
|
|
degree of hairy cell infiltration.
|
|
</p><p id="CDR0000062926__124">After the initiation of treatment with cladribine (2-chlorodeoxyadenosine, 2-CdA),
|
|
pentostatin, or interferon-alpha, the survival rate of patients with advanced
|
|
hairy cell leukemia appears to be higher than 85% at 5 years' follow-up.[<a class="bk_pop" href="#CDR0000062926_rl_3_1">1</a>]</p><div id="CDR0000062926_rl_3"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062926_rl_3_1">Grever MR, Abdel-Wahab O, Andritsos LA, et al.: Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129 (5): 553-560, 2017. [<a href="/pmc/articles/PMC5290982/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5290982</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27903528" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27903528</span></a>]</div></li></ol></div></div><div id="CDR0000062926__10"><h2 id="_CDR0000062926__10_">Treatment Option Overview for Hairy Cell Leukemia</h2><p id="CDR0000062926__11">The initial therapies of choice for hairy cell leukemia are either cladribine (2-chlorodeoxyadenosine,
|
|
2-CdA) or pentostatin.[<a class="bk_pop" href="#CDR0000062926_rl_10_1">1</a>,<a class="bk_pop" href="#CDR0000062926_rl_10_2">2</a>] These drugs have comparable response rates but have
|
|
not been compared in phase III trials. Cladribine is administered as a one-time continuous infusion or series of subcutaneous injections and is
|
|
associated with a high rate of febrile neutropenia.[<a class="bk_pop" href="#CDR0000062926_rl_10_3">3</a>-<a class="bk_pop" href="#CDR0000062926_rl_10_6">6</a>] Rarely, more than one
|
|
course of treatment is required to induce a desirable response. Treatment
|
|
should be discontinued once complete remission or stable partial remission with
|
|
normalization of peripheral blood counts is reached. The presence of residual
|
|
disease may be predictive of relapse but does not seem to affect survival.[<a class="bk_pop" href="#CDR0000062926_rl_10_5">5</a>,<a class="bk_pop" href="#CDR0000062926_rl_10_7">7</a>]
|
|
</p><p id="CDR0000062926__89">The role of consolidation or maintenance therapy in preventing relapse or
|
|
progression of the disease after treatment with purine analogs has not been
|
|
evaluated and remains unproven. Pentostatin is administered intermittently for
|
|
a longer time but may result in a lower incidence of febrile
|
|
complications.[<a class="bk_pop" href="#CDR0000062926_rl_10_8">8</a>,<a class="bk_pop" href="#CDR0000062926_rl_10_9">9</a>] While most patients remain disease free 10 years after
|
|
treatment with these purine analogs, no patient has been monitored long enough
|
|
to assess cure.[<a class="bk_pop" href="#CDR0000062926_rl_10_10">10</a>,<a class="bk_pop" href="#CDR0000062926_rl_10_11">11</a>] Both nucleoside analogs cause profound suppression of CD4
|
|
counts, which may last for a year, and a potential increased risk of second malignancies has been reported.[<a class="bk_pop" href="#CDR0000062926_rl_10_5">5</a>,<a class="bk_pop" href="#CDR0000062926_rl_10_12">12</a>]</p><p id="CDR0000062926__35">
|
|
A study of 3,104 survivors of hairy cell leukemia from the Surveillance, Epidemiology, and End Results (SEER) database showed an increased risk of second cancers (standardized incidence ratio, 1.24; 95% confidence interval, 1.11–1.37), especially for Hodgkin and non-Hodgkin lymphomas.[<a class="bk_pop" href="#CDR0000062926_rl_10_13">13</a>] The increased risk for second cancers was seen even in the two decades before the introduction of purine nucleosides.[<a class="bk_pop" href="#CDR0000062926_rl_10_13">13</a>] With the use of cladribine, an
|
|
increased risk of second malignancies is possible among patients with hairy cell leukemia
|
|
(observed to expected ratio of about 1.8 in several series after 6 years).[<a class="bk_pop" href="#CDR0000062926_rl_10_5">5</a>,<a class="bk_pop" href="#CDR0000062926_rl_10_12">12</a>]
|
|
Several series using pentostatin did not report an increased risk of second
|
|
malignancies.[<a class="bk_pop" href="#CDR0000062926_rl_10_8">8</a>,<a class="bk_pop" href="#CDR0000062926_rl_10_10">10</a>,<a class="bk_pop" href="#CDR0000062926_rl_10_14">14</a>] For a few patients, such as those with severe
|
|
thrombocytopenia, splenectomy might be considered.[<a class="bk_pop" href="#CDR0000062926_rl_10_15">15</a>] After splenectomy,
|
|
50% of patients will require no additional therapy, and long-term survivors
|
|
are common. Therapy with interferon-alpha is another treatment option,
|
|
especially for patients with intercurrent infection.[<a class="bk_pop" href="#CDR0000062926_rl_10_9">9</a>,<a class="bk_pop" href="#CDR0000062926_rl_10_16">16</a>]</p><p id="CDR0000062926__83">The hairy cell leukemia variant has a distinctive phenotype and typically presents with leukocytosis instead of leukopenia.[<a class="bk_pop" href="#CDR0000062926_rl_10_17">17</a>,<a class="bk_pop" href="#CDR0000062926_rl_10_18">18</a>] Patients with this variant have poorer responses to initial cladribine, have shorter durations of response, and typically do not respond again to purine analogs after relapse. Combinations of rituximab and purine analogs are under evaluation, and further studies are required to define optimal therapies.[<a class="bk_pop" href="#CDR0000062926_rl_10_19">19</a>]</p><div id="CDR0000062926_rl_10"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062926_rl_10_1">Gidron A, Tallman MS: 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. Leuk Lymphoma 47 (11): 2301-7, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/17107901" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17107901</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_2">Grever MR, Lozanski G: Modern strategies for hairy cell leukemia. J Clin Oncol 29 (5): 583-90, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21220590" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21220590</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_3">Hoffman MA, Janson D, Rose E, et al.: Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 15 (3): 1138-42, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9060556" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9060556</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_4">Cheson BD, Sorensen JM, Vena DA, et al.: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 16 (9): 3007-15, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9738569" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9738569</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_5">Goodman GR, Burian C, Koziol JA, et al.: Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21 (5): 891-6, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12610190" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12610190</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_6">Jehn U, Bartl R, Dietzfelbinger H, et al.: An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 18 (9): 1476-81, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15229616" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15229616</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_7">Fayad L, Kurzrock R, Keating M, et al.: Treatment of hairy-cell leukemia (HCL) with 2-CdA: long term follow-up at M.D. Anderson Cancer Center. [Abstract] Blood 90 (suppl 1): A-2363, 1997.</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_8">Ribeiro P, Bouaffia F, Peaud PY, et al.: Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 85 (1): 65-71, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/9921975" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9921975</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_9">Grever M, Kopecky K, Foucar MK, et al.: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13 (4): 974-82, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7707126" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7707126</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_10">Flinn IW, Kopecky KJ, Foucar MK, et al.: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96 (9): 2981-6, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/11049974" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11049974</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_11">Chadha P, Rademaker AW, Mendiratta P, et al.: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 106 (1): 241-6, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/15761021" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15761021</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_12">Au WY, Klasa RJ, Gallagher R, et al.: Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood 92 (4): 1160-4, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9694703" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9694703</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_13">Hisada M, Chen BE, Jaffe ES, et al.: Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 99 (3): 215-22, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17284716" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17284716</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_14">Kurzrock R, Strom SS, Estey E, et al.: Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol 15 (5): 1803-10, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9164188" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9164188</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_15">Golomb HM, Vardiman JW: Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 61 (2): 349-52, 1983. [<a href="https://pubmed.ncbi.nlm.nih.gov/6821700" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6821700</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_16">Capnist G, Federico M, Chisesi T, et al.: Long term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of Hairy Cell Leukemia (ICGHCL). Leuk Lymphoma 14 (5-6): 457-64, 1994. [<a href="https://pubmed.ncbi.nlm.nih.gov/7812205" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7812205</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_17">Matutes E, Wotherspoon A, Catovsky D: The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 16 (1): 41-56, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12670464" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12670464</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_18">Arons E, Suntum T, Stetler-Stevenson M, et al.: VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 114 (21): 4687-95, 2009. [<a href="/pmc/articles/PMC2780305/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2780305</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19745070" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19745070</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_10_19">Else M, Osuji N, Forconi F, et al.: The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 110 (10): 2240-7, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17886250" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17886250</span></a>]</div></li></ol></div></div><div id="CDR0000062926__13"><h2 id="_CDR0000062926__13_">Treatment for Hairy Cell Leukemia</h2><p id="CDR0000062926__15">Hairy cell leukemia is a highly treatable disease. Because it is easily
|
|
controlled, many patients have prolonged survival with sequential therapies.
|
|
The decision to treat is based on cytopenias (especially if symptomatic),
|
|
increasing splenomegaly, indications that the disease is progressing, or the
|
|
presence of other, usually infectious, complications. It is reasonable to offer
|
|
no therapy if the patient is asymptomatic and if blood counts are maintained in an
|
|
acceptable range.
|
|
</p><div id="CDR0000062926__145"><h3>Standard Treatment Options for Hairy Cell Leukemia</h3><p id="CDR0000062926__173">Standard treatment options for hairy cell leukemia include the following:</p><ol id="CDR0000062926__146"><li class="half_rhythm"><div><a href="#CDR0000062926__147">Cladribine with or without rituximab</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__152">Pentostatin</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__156">Interferon-alpha</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__160">Splenectomy</a>.</div></li></ol><div id="CDR0000062926__147"><h4>Cladribine with or without rituximab</h4><p id="CDR0000062926__148">Cladribine (2-chlorodeoxyadenosine, 2-CdA) given intravenously by daily subcutaneous injections, or by 2-hour infusions daily for 5 to 7 days results in a complete
|
|
response rate of 50% to 80% and an overall response rate of 85% to 95%.[<a class="bk_pop" href="#CDR0000062926_rl_13_1">1</a>-<a class="bk_pop" href="#CDR0000062926_rl_13_3">3</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence: 3iiiDiv</a>]
|
|
The response rate was lower in 979 patients treated with the Group C mechanism
|
|
of the National Cancer Institute (i.e., 50% complete remission rate, 37% partial
|
|
remission rate). Responses are durable with this short course of therapy,
|
|
and patients who relapse often respond to re-treatment with cladribine.[<a class="bk_pop" href="#CDR0000062926_rl_13_4">4</a>-<a class="bk_pop" href="#CDR0000062926_rl_13_6">6</a>]</p><p id="CDR0000062926__149">Evidence (cladribine with or without rituximab):</p><ol id="CDR0000062926__150"><li class="half_rhythm"><div>A retrospective review included 83 patients, aged 40 years and younger.[<a class="bk_pop" href="#CDR0000062926_rl_13_7">7</a>] <ul id="CDR0000062926__151"><li class="half_rhythm"><div>The median time to first relapse was 54 months for all responders and the median overall survival was 21 years from diagnosis.</div></li><li class="half_rhythm"><div>This
|
|
drug may cause fever and immunosuppression; documented infection was found in 33% of treated patients. </div></li></ul></div></li><li class="half_rhythm"><div>In a retrospective study of patients with
|
|
cladribine-associated neutropenic fever, filgrastim (G-CSF) did not demonstrate
|
|
a decrease in the percentage of febrile patients, number of febrile days, or
|
|
frequency of admissions for antibiotics.[<a class="bk_pop" href="#CDR0000062926_rl_13_8">8</a>] There is a potential increased risk of developing
|
|
second malignancies with this agent.</div></li><li class="half_rhythm"><div>In a randomized phase II study, 68 patients with previously untreated hairy cell leukemia were randomly assigned to receive cladribine 0.15 mg/kg intravenously on days 1 to 5 with 8 weekly doses of rituximab concurrently (starting on day 1) or after 6 months if still positive with minimal residual disease (MRD) testing.[<a class="bk_pop" href="#CDR0000062926_rl_13_9">9</a>]<ul id="CDR0000062926__125"><li class="half_rhythm"><div>With a median follow-up of 96 months, 94% of patients who received concurrent therapy were MRD-free, compared with 12% of patients who received delayed therapy.[<a class="bk_pop" href="#CDR0000062926_rl_13_9">9</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence: 3iiiDiv</a>]</div></li><li class="half_rhythm"><div>Concurrent therapy resulted in more need for platelet transfusions, but also higher neutrophil and platelet counts after one month.</div></li></ul></div></li></ol><p id="CDR0000062926__180">MRD testing in this setting has never been validated as a clinically significant endpoint. This concept requires further study, but hairy cell leukemia is rare, with 600 to 800 new cases annually in the United States.</p></div><div id="CDR0000062926__152"><h4>Pentostatin</h4><p id="CDR0000062926__153">Pentostatin given intravenously every other week for 3 to 6 months produces
|
|
a 50% to 76% complete response rate and an 80% to 87% overall response
|
|
rate.[<a class="bk_pop" href="#CDR0000062926_rl_13_10">10</a>,<a class="bk_pop" href="#CDR0000062926_rl_13_11">11</a>] Complete remissions are of substantial duration. </p><p id="CDR0000062926__162">Evidence (pentostatin):</p><ol id="CDR0000062926__154"><li class="half_rhythm"><div>In two trials
|
|
with 9-year median follow-ups, relapse-free survival ranged from 56% to
|
|
67%.[<a class="bk_pop" href="#CDR0000062926_rl_13_12">12</a>,<a class="bk_pop" href="#CDR0000062926_rl_13_13">13</a>] <ul id="CDR0000062926__155"><li class="half_rhythm"><div>Side effects included fever, immunosuppression, cytopenias, and
|
|
renal dysfunction. </div></li></ul></div></li><li class="half_rhythm"><div>A randomized comparison of pentostatin and interferon-alpha
|
|
demonstrated higher and more durable responses to pentostatin.[<a class="bk_pop" href="#CDR0000062926_rl_13_10">10</a>]</div></li></ol></div><div id="CDR0000062926__156"><h4>Interferon-alpha</h4><p id="CDR0000062926__157">Interferon-alpha given subcutaneously 3 times per week for 1 year yields
|
|
a 10% complete response rate and an 80% overall response rate. The drug
|
|
frequently produces an influenza-like syndrome early in the course of
|
|
treatment. Late effects include depression and lethargy. Responding patients
|
|
who relapse usually react positively to re-treatment with interferon-alpha.[<a class="bk_pop" href="#CDR0000062926_rl_13_14">14</a>] Remission
|
|
can be prolonged with a low-dose maintenance regimen.[<a class="bk_pop" href="#CDR0000062926_rl_13_15">15</a>] </p><p id="CDR0000062926__158">Evidence (interferon-alpha):</p><ol id="CDR0000062926__159"><li class="half_rhythm"><div>A randomized
|
|
comparison of pentostatin and interferon-alpha demonstrated significantly higher
|
|
and more durable responses to pentostatin.[<a class="bk_pop" href="#CDR0000062926_rl_13_10">10</a>]</div></li></ol></div><div id="CDR0000062926__160"><h4>Splenectomy</h4><p id="CDR0000062926__161">Splenectomy will partially or completely normalize the peripheral blood in
|
|
the vast majority of patients with hairy cell leukemia.[<a class="bk_pop" href="#CDR0000062926_rl_13_16">16</a>] Usually
|
|
little or no change occurs in the bone marrow after splenectomy, and virtually all
|
|
patients have progressive disease within 12 to 18 months. Therefore, because a
|
|
number of more effective alternatives are available, splenectomy is playing a
|
|
decreasing role in the treatment of this disease.
|
|
</p></div></div><div id="CDR0000062926__TrialSearch_13_sid_4"><h3>Current Clinical Trials</h3><p id="CDR0000062926__TrialSearch_13_22">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062926_rl_13"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062926_rl_13_1">Robak T, Błasińska-Morawiec M, Krykowski E, et al.: 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 22 (1-2): 107-11, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8724536" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8724536</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_2">Robak T, Jamroziak K, Gora-Tybor J, et al.: Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 109 (9): 3672-5, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17209059" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17209059</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_3">Zenhäusern R, Schmitz SF, Solenthaler M, et al.: Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma 50 (9): 1501-11, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19672771" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19672771</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_4">Jehn U, Bartl R, Dietzfelbinger H, et al.: An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 18 (9): 1476-81, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15229616" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15229616</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_5">Chadha P, Rademaker AW, Mendiratta P, et al.: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 106 (1): 241-6, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/15761021" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15761021</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_6">Else M, Dearden CE, Matutes E, et al.: Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145 (6): 733-40, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19344416" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19344416</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_7">Rosenberg JD, Burian C, Waalen J, et al.: Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood 123 (2): 177-83, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24192579" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24192579</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_8">Saven A, Burian C, Adusumalli J, et al.: Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 93 (8): 2471-7, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10194424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10194424</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_9">Chihara D, Arons E, Stetler-Stevenson M, et al.: Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. J Clin Oncol 38 (14): 1527-1538, 2020. [<a href="/pmc/articles/PMC7213585/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7213585</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32109194" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32109194</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_10">Grever M, Kopecky K, Foucar MK, et al.: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13 (4): 974-82, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7707126" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7707126</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_11">Ribeiro P, Bouaffia F, Peaud PY, et al.: Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 85 (1): 65-71, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/9921975" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9921975</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_12">Johnston JB, Eisenhauer E, Wainman N, et al.: Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol 27 (2 Suppl 5): 32-6, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10877049" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10877049</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_13">Flinn IW, Kopecky KJ, Foucar MK, et al.: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96 (9): 2981-6, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/11049974" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11049974</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_14">Golomb HM, Ratain MJ, Fefer A, et al.: Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia. J Natl Cancer Inst 80 (5): 369-73, 1988. [<a href="https://pubmed.ncbi.nlm.nih.gov/3282078" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3282078</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_15">Capnist G, Federico M, Chisesi T, et al.: Long term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of Hairy Cell Leukemia (ICGHCL). Leuk Lymphoma 14 (5-6): 457-64, 1994. [<a href="https://pubmed.ncbi.nlm.nih.gov/7812205" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7812205</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_16">Golomb HM, Vardiman JW: Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 61 (2): 349-52, 1983. [<a href="https://pubmed.ncbi.nlm.nih.gov/6821700" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6821700</span></a>]</div></li></ol></div></div><div id="CDR0000062926__22"><h2 id="_CDR0000062926__22_">Relapsed or Refractory Hairy Cell Leukemia</h2><div id="CDR0000062926__127"><h3>Treatment Options for Relapsed or Refractory Hairy Cell Leukemia</h3><p id="CDR0000062926__174">Treatment options for relapsed or refractory hairy cell leukemia include the following:</p><ol id="CDR0000062926__128"><li class="half_rhythm"><div><a href="#CDR0000062926__129">Re-treatment with cladribine or pentostatin</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__131">Rituximab</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__133">Purine analog plus rituximab</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__135">Vemurafenib with or without rituximab</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__137">Moxemutomab pasudotox-tdfk</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__139">Ibrutinib</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__141">Interferon-alpha</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__143">Splenectomy</a>.</div></li></ol><div id="CDR0000062926__129"><h4>Re-treatment with cladribine or pentostatin</h4><p id="CDR0000062926__130">Patients with hairy cell leukemia who relapse after the first course of cladribine or pentostatin often respond
|
|
well to re-treatment with the same or another purine analog, especially if relapse occurs after 2 years.[<a class="bk_pop" href="#CDR0000062926_rl_22_1">1</a>-<a class="bk_pop" href="#CDR0000062926_rl_22_6">6</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence: 3iiiDiv</a>]</p></div><div id="CDR0000062926__131"><h4>Rituximab</h4><p id="CDR0000062926__132">Rituximab can induce durable complete remissions with minimal toxic effects in patients with multiple relapsing or refractory disease after purine analog therapy or after treatment with interferon.[<a class="bk_pop" href="#CDR0000062926_rl_22_7">7</a>-<a class="bk_pop" href="#CDR0000062926_rl_22_11">11</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence: 3iiiDiv</a>] </p></div><div id="CDR0000062926__133"><h4>Purine analog plus rituximab</h4><p id="CDR0000062926__134">Combinations or the sequential use of rituximab with either cladribine or pentostatin are effective in achieving complete remission and are under clinical evaluation.[<a class="bk_pop" href="#CDR0000062926_rl_22_12">12</a>-<a class="bk_pop" href="#CDR0000062926_rl_22_15">15</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence: 3iiiDiv</a>]</p></div><div id="CDR0000062926__135"><h4>Vemurafenib with or without rituximab</h4><p id="CDR0000062926__136"> The <i>BRAF</i>-V600E mutation occurs in almost 100% of classic-form hairy cell leukemia patients and almost never in other B-cell lymphomas and leukemias, including hairy cell leukemia variants.[<a class="bk_pop" href="#CDR0000062926_rl_22_16">16</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence: 3iiiDiv</a>] Vemurafenib can be given in combination with rituximab.</p><p id="CDR0000062926__168">Evidence (vemurafenib with or without rituximab):</p><ol id="CDR0000062926__169"><li class="half_rhythm"><div>Two phase II, multicenter studies in the United States and Italy evaluated the BRAF inhibitor vemurafenib, given orally for 4 months.[<a class="bk_pop" href="#CDR0000062926_rl_22_17">17</a>,<a class="bk_pop" href="#CDR0000062926_rl_22_18">18</a>] <ul id="CDR0000062926__170"><li class="half_rhythm"><div>After a median follow-up of 23 months, the overall response rate for 50 patients was 98%, the complete response rate was 38%, and the median treatment-free survival was 25 months and 18 months in the two studies.[<a class="bk_pop" href="#CDR0000062926_rl_22_17">17</a>,<a class="bk_pop" href="#CDR0000062926_rl_22_18">18</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of Evidence: 3iiiDiv</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062926__137"><h4>Moxemutomab pasudotox-tdfk</h4><p id="CDR0000062926__175">Moxemutomab pasudotox-tdfk is an anti-CD22 recombinant immunotoxin that was approved by the U.S. Food and Drug Administration to treat patients with relapsed or refractory disease.[<a class="bk_pop" href="#CDR0000062926_rl_22_19">19</a>-<a class="bk_pop" href="#CDR0000062926_rl_22_22">22</a>]</p><p id="CDR0000062926__176">Evidence (moxemutomab pasudotox-tdfk):</p><ol id="CDR0000062926__177"><li class="half_rhythm"><div>Moxemutomab pasudotox-tdfk was given to 80 patients who were previously treated with at least two regimens.[<a class="bk_pop" href="#CDR0000062926_rl_22_23">23</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence: 3iiiDiv</a>] <ul id="CDR0000062926__178"><li class="half_rhythm"><div>In a phase II trial, 75% of patients responded and 30% had a complete response.</div></li></ul></div></li></ol></div><div id="CDR0000062926__139"><h4>Ibrutinib</h4><p id="CDR0000062926__140">Evidence (ibrutinib):</p><ol id="CDR0000062926__179"><li class="half_rhythm"><div>In a phase II study, reported in abstract form, 28 patients with refractory hairy cell leukemia had a 48% response rate to ibrutinib.[<a class="bk_pop" href="#CDR0000062926_rl_22_24">24</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence: 3iiiDiv</a>]</div></li></ol></div><div id="CDR0000062926__141"><h4>Interferon-alpha</h4><p id="CDR0000062926__142">Interferon-alpha and splenectomy are therapeutic options that can be considered when other options have been exhausted (Refer to the section on <a href="#CDR0000062926__156">Interferon-alpha</a> in the <a href="#CDR0000062926__145">Standard Treatment Options for Hairy Cell Leukemia </a> section.)[<a class="bk_pop" href="#CDR0000062926_rl_22_25">25</a>-<a class="bk_pop" href="#CDR0000062926_rl_22_27">27</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence: 3iiiDiv</a>].</p></div><div id="CDR0000062926__143"><h4>Splenectomy</h4><p id="CDR0000062926__144">Interferon-alpha and splenectomy are therapeutic options that can be considered when other options have been exhausted.[<a class="bk_pop" href="#CDR0000062926_rl_22_28">28</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000587991/" class="def">Level of evidence: 3iiiDiv</a>]</p></div></div><div id="CDR0000062926__TrialSearch_22_sid_5"><h3>Current Clinical Trials</h3><p id="CDR0000062926__TrialSearch_22_22">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062926_rl_22"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062926_rl_22_1">Hoffman MA, Janson D, Rose E, et al.: Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol 15 (3): 1138-42, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9060556" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9060556</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_2">Goodman GR, Burian C, Koziol JA, et al.: Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21 (5): 891-6, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12610190" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12610190</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_3">Ribeiro P, Bouaffia F, Peaud PY, et al.: Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 85 (1): 65-71, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/9921975" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9921975</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_4">Zinzani PL, Magagnoli M, Bendandi M, et al.: Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. Haematologica 85 (9): 922-5, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10980629" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10980629</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_5">Gidron A, Tallman MS: 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. Leuk Lymphoma 47 (11): 2301-7, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/17107901" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17107901</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_6">Else M, Dearden CE, Matutes E, et al.: Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145 (6): 733-40, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19344416" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19344416</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_7">Gerrie AS, Zypchen LN, Connors JM: Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 119 (9): 1988-91, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22223825" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22223825</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_8">Hagberg H, Lundholm L: Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 115 (3): 609-11, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11736943" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11736943</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_9">Lauria F, Lenoci M, Annino L, et al.: Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 86 (10): 1046-50, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11602410" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11602410</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_10">Thomas DA, O'Brien S, Bueso-Ramos C, et al.: Rituximab in relapsed or refractory hairy cell leukemia. Blood 102 (12): 3906-11, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12816862" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12816862</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_11">Angelopoulou MK, Pangalis GA, Sachanas S, et al.: Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab. Leuk Lymphoma 49 (9): 1817-20, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18798112" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18798112</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_12">Ravandi F, O'Brien S, Jorgensen J, et al.: Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118 (14): 3818-23, 2011. [<a href="/pmc/articles/PMC4081440/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4081440</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21821712" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21821712</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_13">Else M, Dearden CE, Matutes E, et al.: Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 52 (Suppl 2): 75-8, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21504288" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21504288</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_14">Chihara D, Kantarjian H, O'Brien S, et al.: Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 174 (5): 760-6, 2016. [<a href="/pmc/articles/PMC5396841/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5396841</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27301277" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27301277</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_15">Chihara D, Arons E, Stetler-Stevenson M, et al.: Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. J Clin Oncol 38 (14): 1527-1538, 2020. [<a href="/pmc/articles/PMC7213585/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7213585</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32109194" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32109194</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_16">Pettirossi V, Santi A, Imperi E, et al.: BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood 125 (8): 1207-16, 2015. [<a href="/pmc/articles/PMC4366655/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4366655</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25480661" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25480661</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_17">Tiacci E, Park JH, De Carolis L, et al.: Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med 373 (18): 1733-47, 2015. [<a href="/pmc/articles/PMC4811324/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4811324</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26352686" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26352686</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_18">Dietrich S, Pircher A, Endris V, et al.: BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 127 (23): 2847-55, 2016. [<a href="https://pubmed.ncbi.nlm.nih.gov/26941398" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26941398</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_19">Kreitman RJ, Tallman MS, Robak T, et al.: Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood 131 (21): 2331-2334, 2018. [<a href="/pmc/articles/PMC5969375/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5969375</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29487070" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29487070</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_20">Kreitman RJ, Wilson WH, White JD, et al.: Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18 (8): 1622-36, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10764422" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10764422</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_21">Kreitman RJ, Stetler-Stevenson M, Margulies I, et al.: Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27 (18): 2983-90, 2009. [<a href="/pmc/articles/PMC2702232/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2702232</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19414673" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19414673</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_22">Kreitman RJ, Tallman MS, Robak T, et al.: Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30 (15): 1822-8, 2012. [<a href="/pmc/articles/PMC3383181/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3383181</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22355053" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22355053</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_23">Kreitman RJ, Dearden C, Zinzani PL, et al.: Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 32 (8): 1768-1777, 2018. [<a href="/pmc/articles/PMC6087717/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6087717</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30030507" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30030507</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_24">Jones J, Andritsos L, Kreitman RJ: Efficacy and safety of the Bruton tyrosine kinase inhibitor ibrutinib in patients with hairy cell leukemia: stage 1 results of a phase 2 study. [Abstract] Blood 128 (22): A-1215, 2016.</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_25">Grever M, Kopecky K, Foucar MK, et al.: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13 (4): 974-82, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7707126" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7707126</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_26">Golomb HM, Ratain MJ, Fefer A, et al.: Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia. J Natl Cancer Inst 80 (5): 369-73, 1988. [<a href="https://pubmed.ncbi.nlm.nih.gov/3282078" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3282078</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_27">Capnist G, Federico M, Chisesi T, et al.: Long term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of Hairy Cell Leukemia (ICGHCL). Leuk Lymphoma 14 (5-6): 457-64, 1994. [<a href="https://pubmed.ncbi.nlm.nih.gov/7812205" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7812205</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_22_28">Golomb HM, Vardiman JW: Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 61 (2): 349-52, 1983. [<a href="https://pubmed.ncbi.nlm.nih.gov/6821700" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6821700</span></a>]</div></li></ol></div></div><div id="CDR0000062926__32"><h2 id="_CDR0000062926__32_">Changes to This Summary (11/25/2020)</h2><p id="CDR0000062926__33">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</p><p id="CDR0000062926__181"><b><a href="#CDR0000062926__13">Treatment Options for Hairy Cell Leukemia</a></b></p><p id="CDR0000062926__182">Added <a href="/books/NBK65741.4/#CDR0000062926__150">text</a> to state that in a randomized phase II study, 68 patients with previously untreated hairy cell leukemia were randomly assigned to receive cladribine 0.15 mg/kg intravenously on days 1 to 5 with 8 weekly doses of rituximab concurrently or after 6 months if still positive with minimal residual disease (MRD) testing. With a median follow-up of 96 months, 94% of patients who received concurrent therapy were MRD-free compared with 12% of patients who received delayed therapy [cited Chihara et al. as reference 9 and level of evidence 3iiiDiv).</p><p id="CDR0000062926__183">Added <a href="#CDR0000062926__180">text</a> to state that MRD testing in this setting has never been validated as a clinically significant endpoint; this concept requires further study, but hairy cell leukemia is rare, with 600 to 800 new cases annually in the United States.</p><p id="CDR0000062926__117"><b><a href="#CDR0000062926__22">Relapsed or Refractory Hairy Cell Leukemia</a></b></p><p id="CDR0000062926__184">Revised <a href="#CDR0000062926__130">text</a> to state that patients with hairy cell leukemia who relapse after the first course of cladribine or pentostatin often respond well to re-treatment with the same or another purine analog, especially if relapse occurs after 2 years.</p><p id="CDR0000062926__185">Added <a href="#CDR0000062926__136">text</a> to state that vemurafenib can be given in combination with rituximab.</p><p id="CDR0000062926__186">Added <a href="#CDR0000062926__137">Moxemutomab pasudotox-tdfk</a> as a new subsection.</p><p id="CDR0000062926__188">Added <a href="/books/NBK65741.4/#CDR0000062926__179">text</a> to state that in a phase II study, reported in abstract form, 28 patients with refractory hairy cell leukemia had a 48% response rate to ibrutinib (cited Jones et al. as reference 24 and level of evidence: 3iiiDiv).</p><p id="CDR0000062926__disclaimerHP_3">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Adult Treatment Editorial Board</a>, which is
|
|
editorially independent of NCI. The summary reflects an independent review of
|
|
the literature and does not represent a policy statement of NCI or NIH. More
|
|
information about summary policies and the role of the PDQ Editorial Boards in
|
|
maintaining the PDQ summaries can be found on the <a href="#CDR0000062926__AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ® - NCI's Comprehensive Cancer Database</a> pages.
|
|
</p></div><div id="CDR0000062926__AboutThis_1"><h2 id="_CDR0000062926__AboutThis_1_">About This PDQ Summary</h2><div id="CDR0000062926__AboutThis_2"><h3>Purpose of This Summary</h3><p id="CDR0000062926__AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of hairy cell leukemia. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p></div><div id="CDR0000062926__AboutThis_4"><h3>Reviewers and Updates</h3><p id="CDR0000062926__AboutThis_5">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Adult Treatment Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="CDR0000062926__AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</p><ul id="CDR0000062926__AboutThis_6"><li class="half_rhythm"><div>be discussed at a meeting,</div></li><li class="half_rhythm"><div>be cited with text, or</div></li><li class="half_rhythm"><div>replace or update an existing article that is already cited.</div></li></ul><p id="CDR0000062926__AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.</p><p>The lead reviewers for Hairy Cell Leukemia Treatment are:</p><ul><li class="half_rhythm"><div>Eric J. Seifter, MD (Johns Hopkins University)</div></li><li class="half_rhythm"><div>Mikkael A. Sekeres, MD, MS (Cleveland Clinic Taussig Cancer Institute)</div></li></ul><p id="CDR0000062926__AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></div><div id="CDR0000062926__AboutThis_10"><h3>Levels of Evidence</h3><p id="CDR0000062926__AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <a href="/books/n/pdqcis/CDR0000062796/">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></div><div id="CDR0000062926__AboutThis_12"><h3>Permission to Use This Summary</h3><p id="CDR0000062926__AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</p><p id="CDR0000062926__AboutThis_14">The preferred citation for this PDQ summary is:</p><p id="CDR0000062926__AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Hairy Cell Leukemia Treatment. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: <a href="https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq</a>. Accessed <MM/DD/YYYY>. [PMID: 26389184]</p><p id="CDR0000062926__AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Visuals Online</a>, a collection of over 2,000 scientific images.
|
|
</p></div><div id="CDR0000062926__AboutThis_17"><h3>Disclaimer</h3><p id="CDR0000062926__AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Managing Cancer Care</a> page.</p></div><div id="CDR0000062926__AboutThis_20"><h3>Contact Us</h3><p id="CDR0000062926__AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website’s <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>.</p></div></div></div></div>
|
|
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK65741</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26389184" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">26389184</a></span></div></div></div>
|
|
|
|
</div>
|
|
|
|
<!-- Custom content below content -->
|
|
<div class="col4">
|
|
|
|
</div>
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<!-- Custom contetnt below bottom nav -->
|
|
<div class="col5">
|
|
|
|
</div>
|
|
</div>
|
|
|
|
<div id="rightcolumn" class="four_col col last">
|
|
<!-- Custom content above discovery portlets -->
|
|
<div class="col6">
|
|
<div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK65741&db=books">Share</a></div>
|
|
|
|
</div>
|
|
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK65741.4/?report=reader">PubReader</a></li><li><a href="/books/NBK65741.4/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK65741" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK65741" style="display:none" title="Cite this Page"><div class="bk_tt">PDQ Adult Treatment Editorial Board. Hairy Cell Leukemia Treatment (PDQ®): Health Professional Version. 2020 Nov 25. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. <span class="bk_cite_avail"></span></div></div></li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Version History</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter shutter_closed" title="Show/hide content" remembercollapsed="true" pgsec_name="version_history" id="Shutter"></a></div><div class="portlet_content" style="display: none;"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><span class="bk_col_itm"><a href="/books/NBK65741.9/">NBK65741.9</a></span> September 20, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65741.8/">NBK65741.8</a></span> February 9, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65741.7/">NBK65741.7</a></span> December 21, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65741.6/">NBK65741.6</a></span> January 14, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65741.5/">NBK65741.5</a></span> December 17, 2020</li><li><span class="bk_col_itm">NBK65741.4</span> November 25, 2020 (Displayed Version)</li><li><span class="bk_col_itm"><a href="/books/NBK65741.3/">NBK65741.3</a></span> March 23, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK65741.2/">NBK65741.2</a></span> March 18, 2016</li><li><span class="bk_col_itm"><a href="/books/NBK65741.1/">NBK65741.1</a></span> July 8, 2015</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this Page</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#CDR0000062926__1" ref="log$=inpage&link_id=inpage">General Information About Hairy Cell Leukemia</a></li><li><a href="#CDR0000062926__3" ref="log$=inpage&link_id=inpage">Stage Information for Hairy Cell Leukemia</a></li><li><a href="#CDR0000062926__10" ref="log$=inpage&link_id=inpage">Treatment Option Overview for Hairy Cell Leukemia</a></li><li><a href="#CDR0000062926__13" ref="log$=inpage&link_id=inpage">Treatment for Hairy Cell Leukemia</a></li><li><a href="#CDR0000062926__22" ref="log$=inpage&link_id=inpage">Relapsed or Refractory Hairy Cell Leukemia</a></li><li><a href="#CDR0000062926__32" ref="log$=inpage&link_id=inpage">Changes to This Summary (11/25/2020)</a></li><li><a href="#CDR0000062926__AboutThis_1" ref="log$=inpage&link_id=inpage">About This PDQ Summary</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related publications</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK65807/">Patient Version</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&DbFrom=books&Cmd=Link&LinkName=books_pmc_refs&IdsFromResult=2823214" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&DbFrom=books&Cmd=Link&LinkName=books_pubmed_refs&IdsFromResult=2823214" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389356" ref="ordinalpos=1&linkpos=1&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Urethral Cancer Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Urethral Cancer Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Adult Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389236" ref="ordinalpos=1&linkpos=2&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Parathyroid Cancer Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Parathyroid Cancer Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Adult Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389173" ref="ordinalpos=1&linkpos=3&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Delirium (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Delirium (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27583328" ref="ordinalpos=1&linkpos=4&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Financial Toxicity and Cancer Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Financial Toxicity and Cancer Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Adult Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389450" ref="ordinalpos=1&linkpos=5&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Myelodysplastic Syndromes Treatment (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Myelodysplastic Syndromes Treatment (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Adult Treatment Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed_reviews&uid=26389184" ref="ordinalpos=1&log$=relatedreviews_seeall&logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=26389184" ref="ordinalpos=1&log$=relatedarticles_seeall&logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=67c965d8b15b832ebc9655b2">Hairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries</a><div class="ralinkpop offscreen_noflow">Hairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=2" href="/portal/utils/pageresolver.fcgi?recordid=67c965c5f4a390645ebb43f5">Sleep Disorders (PDQ®) - PDQ Cancer Information Summaries</a><div class="ralinkpop offscreen_noflow">Sleep Disorders (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=3" href="/portal/utils/pageresolver.fcgi?recordid=67c96571b15b832ebc92ca05">Vulvar Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries</a><div class="ralinkpop offscreen_noflow">Vulvar Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
|
|
|
|
<!-- Custom content below discovery portlets -->
|
|
<div class="col7">
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
<!-- Custom content after all -->
|
|
<div class="col8">
|
|
|
|
</div>
|
|
<div class="col9">
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
|
|
<script type="text/javascript">
|
|
(function($){
|
|
$('.skiplink').each(function(i, item){
|
|
var href = $($(item).attr('href'));
|
|
href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
|
|
$(item).on('click', function(event){
|
|
event.preventDefault();
|
|
$.scrollTo(href, 0, {
|
|
onAfter: function(){
|
|
href.focus();
|
|
}
|
|
});
|
|
});
|
|
});
|
|
})(jQuery);
|
|
</script>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<div class="footer" id="footer">
|
|
<section class="icon-section">
|
|
<div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
|
|
<div class="grid-container container">
|
|
<div class="icon-section_container">
|
|
<a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11 {
|
|
fill: #737373;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>Twitter</title>
|
|
<path class="cls-11" d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>Facebook</title>
|
|
<path class="cls-11" d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_linkedin" href="https://www.linkedin.com/company/ncbinlm" aria-label="LinkedIn"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>LinkedIn</title>
|
|
<path class="cls-11" d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11,
|
|
.cls-12 {
|
|
fill: #737373;
|
|
}
|
|
|
|
.cls-11 {
|
|
fill-rule: evenodd;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>GitHub</title>
|
|
<path class="cls-11" d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
|
|
</path>
|
|
<path class="cls-12" d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
|
|
</path>
|
|
<path class="cls-12" d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
|
|
</path>
|
|
<path class="cls-12" d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
|
|
<path class="cls-12" d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
|
|
<svg xmlns="http://www.w3.org/2000/svg" id="Layer_1" data-name="Layer 1" viewBox="0 0 40 40">
|
|
<defs><style>.cls-1{fill:#737373;}</style></defs>
|
|
<title>NCBI Insights Blog</title>
|
|
<path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"></path>
|
|
</svg>
|
|
</a>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
|
|
<section class="container-fluid bg-primary">
|
|
<div class="container pt-5">
|
|
<div class="row mt-3">
|
|
<div class="col-lg-3 col-12">
|
|
<p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
|
|
<ul class="list-inline social_media">
|
|
<li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st20 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st30 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Twitter</title>
|
|
<g>
|
|
<g>
|
|
<g>
|
|
<path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7 c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116 c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3 c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6 C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
|
|
</g>
|
|
</svg></a></li>
|
|
<li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine" aria-label="Facebook" rel="noopener noreferrer" target="_blank">
|
|
<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st10 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st110 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Facebook</title>
|
|
<g>
|
|
<g>
|
|
<path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9 v67.5H135v-67.5h21.7L159,99.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
|
|
</svg>
|
|
</a></li>
|
|
<li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<title>Youtube</title>
|
|
<style type="text/css">
|
|
.st4 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
|
|
.st5 {
|
|
fill: #FFFFFF;
|
|
}
|
|
</style>
|
|
<circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
|
|
<g transform="translate(0,-952.36218)">
|
|
<path class="st5" d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7 v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
|
|
</g>
|
|
</svg></a></li>
|
|
</ul>
|
|
</div>
|
|
<div class="col-lg-3 col-12">
|
|
<p class="address_footer text-white">National Library of Medicine<br />
|
|
<a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323" class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br />
|
|
Bethesda, MD 20894</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br />
|
|
<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="text-white">FOIA</a><br />
|
|
<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br />
|
|
<a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br />
|
|
<a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
|
|
</div>
|
|
</div>
|
|
<div class="row">
|
|
<div class="col-lg-12 centered-lg">
|
|
<nav class="bottom-links">
|
|
<ul class="mt-3">
|
|
<li>
|
|
<a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.nih.gov/">NIH</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.hhs.gov/">HHS</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.usa.gov/">USA.gov</a>
|
|
</li>
|
|
</ul>
|
|
</nav>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK65741&ncbi_domain=pdqcis&ncbi_report=record&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK65741.4/&ncbi_pagename=Hairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf&ncbi_bookparttype=chapter&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4209313/4212053/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |